KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Receivables: 2018-2025

Historic Receivables for Twist Bioscience (TWST) over the last 7 years, with Sep 2025 value amounting to $60.9 million.

  • Twist Bioscience's Receivables rose 64.82% to $60.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $204.3 million, marking a year-over-year increase of 38.00%. This contributed to the annual value of $60.9 million for FY2025, which is 64.82% up from last year.
  • As of Q3 2025, Twist Bioscience's Receivables stood at $60.9 million, which was up 19.62% from $50.9 million recorded in Q2 2025.
  • In the past 5 years, Twist Bioscience's Receivables ranged from a high of $60.9 million in Q3 2025 and a low of $30.4 million during Q1 2021.
  • Its 3-year average for Receivables is $45.5 million, with a median of $46.9 million in 2023.
  • In the last 5 years, Twist Bioscience's Receivables soared by 132.29% in 2021 and then declined by 28.16% in 2024.
  • Over the past 5 years, Twist Bioscience's Receivables (Quarterly) stood at $32.9 million in 2021, then skyrocketed by 51.17% to $49.7 million in 2022, then decreased by 23.82% to $37.9 million in 2023, then climbed by 8.71% to $41.2 million in 2024, then surged by 64.82% to $60.9 million in 2025.
  • Its last three reported values are $60.9 million in Q3 2025, $50.9 million for Q2 2025, and $51.4 million during Q1 2025.